Melatonin Alleviates Retina Angiogenesis by Targeting Fibronectin and the VEGF Pathway
The FASEB Journal · 2025
DOI: 10.1096/fj.202500814rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Fang Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hunan Key Laboratory of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Melatonin, Fibronectins, Vascular Endothelial Growth Factor A, Retinal Neovascularization. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), HSTD | Natural Science Foundation of Hunan Province ( ), Central South University.
Abstract (Originalsprache)
Diabetic retinopathy (DR) and retinopathy of prematurity (ROP) continue to be significant causes of vision impairment despite the well‐established role of vascular endothelial growth factor (VEGF) in pathological angiogenesis. We still need to deeply understand retinal angiogenesis's molecular mechanisms and identify potential alternate therapeutic targets. We used RNA sequencing (RNA‐seq) and found fibronectin ( FN1 ), an extracellular matrix protein, was significantly upregulated during retinal angiogenesis in the oxygen‐induced retinopathy (OIR) model. Employing a deep learning model (BioNet) to identify potential FN1 inhibitors among FDA‐approved drugs, we discovered that melatonin effectively reduced FN1 expression and inhibited VEGF‐induced angiogenesis by decreasing VEGFR2 phosphorylation. In vivo, melatonin administration significantly reduced preretinal tufts in the OIR model while suppressing FN1 expression and VEGFR2 activation. This study highlights the power of computer‐driven drug discovery, with BioNet successfully identifying melatonin as a potential therapeutic agent for retinal angiogenesis. The ability of melatonin to inhibit both FN1 and VEGF signaling highlights the potential of integrating advanced computational methods with rigorous experimental validation to uncover novel therapies for complex diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Hunan Key Laboratory of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China.
- Huan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
- College of Computer Science and Technology, National University of Defense Technology, Changsha, Hunan, China.
- National key Laboratory of Parallel and Distributed Computing, National University of Defense Technology, Changsha, Hunan, China.
- Human Resources Department, Shenzhen Children's Hospital, Shenzhen, China.
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- HSTD | Natural Science Foundation of Hunan Province ( )
- Central South University
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Chen, F., Yang, X., Yin, Y., Meng, Z., Wu, Z., Liu, D., Wu, C., Luo, J., & Wu, W. (2025). Melatonin Alleviates Retina Angiogenesis by Targeting Fibronectin and the VEGF Pathway. The FASEB Journal. https://doi.org/10.1096/fj.202500814rr
Vancouver
Chen F, Yang X, Yin Y, Meng Z, Wu Z, Liu D, et al. Melatonin Alleviates Retina Angiogenesis by Targeting Fibronectin and the VEGF Pathway. The FASEB Journal. 2025. doi:10.1096/fj.202500814rr
BibTeX
@article{Chen2025,
author = {Chen, Fang and Yang, Xi and Yin, Yiwei and Meng, Zhishang and Wu, Ze and Liu, Dan and Wu, Chengkun and Luo, Jing and Wu, Wenyi},
title = {Melatonin Alleviates Retina Angiogenesis by Targeting Fibronectin and the VEGF Pathway},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500814rr}
}
EUVIMED